Special Issue "Drugs Targeting the Disease Progression, Cognitive Impairment, Anxiety and Other Co-morbidities in Epilepsy: From Bench to Bedside"
Deadline for manuscript submissions: 15 December 2023 | Viewed by 1326
Interests: neuroscience pharmacology; toxicology and pharmaceutics chemistry psychology biochemistry; genetics and molecular biology arts and humanities
Interests: adenosine; neuromodulation; neuromuscular junction; epilepsy; osteogenic differentiation; fibrosis; mesenchymal stem cells (MSCs)
Until now, epilepsy therapy has mainly focused on anticonvulsant drugs with negligible disease modifying properties. Despite the increasing implication of non-canonical neurotransmitter systems in epilepsy, this knowledge has not been sufficiently translated into clinical practice to decrease epileptogenesis progression and accompanying neuropsychiatric co-morbidities. For instance, brain monoaminergic circuits are important regulators of synaptic plasticity and acute stress responses ultimately involved in epilepsy-induced anxiety and memory impairment, but only a few studies have proven that these circuits are altered in epilepsy. Likewise, central cholinergic system adaptations are also associated with epileptogenesis. Both monoaminergic and cholinergic brain circuits frequently target cortical interneurons, expressing a myriad of neuropeptide co-transmitters in distinct cortical areas including the hippocampus, the amygdala, and the prefrontal cortex, all involved in emotional control of cognition. On the other hand, brain neuropeptides released during high-frequency and repetitive discharges may also foster neuronal hyperexcitability states, thus facilitating seizures recurrence and chronic epilepsy. This Special Issue aims to receive high-quality original research papers and review articles focusing on novel drug targets to control epilepsy progression and neuropsychiatric co-morbidities from bench to bedside and bedside to bench perspectives.
Dr. Diana Cunha-Reis
Dr. Paulo Correia-de-Sá
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- epilepsy and epileptogenesis
- aminergic neurotransmission
- neuropeptidergic neuromodulation
- cognitive impairment
- neuropsychiatric co-morbidities